| Product Name | Mouse anti-Cytokeratin 20, Clone K2 20.8 (monoclonal) |
|---|---|
| Description | Mouse anti-Cytokeratin 20, Clone K2 20.8 (monoclonal) |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | Ks20.8 |
| Immunogen | Cytoskeletal preparation isolated from microdissected villi of human duodenal mucosa. |
| Isotype | IgG2a, kappa |
| Reactivity | Human |
| Applications | IHC-P |
| Working Dilutions | IHC-P (1:50) |
| Diluent Buffer | PBS (pH 7.6) with 1% BSA and sodium azide |
| Concentration | Greater than or equal to 9,26 mg/L |
| Storage | 2-8°C |
| Notes | Cytokeratin 20 has been demonstrated to be almost entirely confined to the gastric and intestinal epithelium, urothelium and Merkel cells of the skin. Cytokeratin 20 is less acidic than other type I cytokeratins and is of interest due to its restricted tissue expression. In normal tissue, cytokeratin 20 is expressed in intestinal epithelium, gastric foveolar epithelium, a number of endocrine cells in the upper portions of the pyloric glands, urothelium and Merkel cells in epidermis. In tumors it is reported, there is a marked difference in the expression of cytokeratin 20 within different carcinomas. Neoplasms expressing cytokeratin 20 are derived from normal epithelia which themselves expressed cytokeratin 20. Colorectal carcinomas consistently express cytokeratin 20, while gastric adenocarcinomas express cytokeratin 20 to a lesser degree. Adenocarcinomas of the gall bladder and bile duct, ductal cell adenocarcinomas of the pancreas, mucinous ovarian tumors, Merkel cell tumors and transitional cell carcinomas have also been reported to express cytokeratin 20. |
| References | Botta MC et al. Pathologica. 2001; 93(6):640-644. Leech SN et al. Journal of Clinical Pathology. 2001; 54:727-729. Tan J et al. Human Pathology. 1998; 29(4):390-396. Longatto Filho A et al. Acta Cytol. 1997; 41(4):961-971. Moll R et al. American Journal of Pathology. 1992; 140(2):427-447 |
| Supplier | MONOSAN |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
